Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C61329
http://purl.obolibrary.org/obo/NCIT_C61329
|
|---|---|
| Preferred Name | Nastorazepide Calcium |
| Definitions |
A selective, orally available, 1,5-benzodiazepine-derivative gastrin/cholecystokinin 2 (CCK-2) receptor antagonist with potential antineoplastic activity. Z-360 binds to the gastrin/CCK-2 receptor, thereby preventing receptor activation by gastrin, a peptide hormone frequently associated with the proliferation of gastrointestinal and pancreatic tumor cells.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A selective, orally available, 1,5-benzodiazepine-derivative gastrin/cholecystokinin 2 (CCK-2) receptor antagonist with potential antineoplastic activity. Z-360 binds to the gastrin/CCK-2 receptor, thereby preventing receptor activation by gastrin, a peptide hormone frequently associated with the proliferation of gastrointestinal and pancreatic tumor cells. |
|---|---|
| prefLabel | Nastorazepide Calcium
|
| label | Nastorazepide Calcium
|
| NCI_META_CUI | CL937292
|
| PDQ_Closed_Trial_Search_ID | 485295
|
| code | C61329
|
| prefixIRI | NCIT:C61329
|
| in_subset | |
| Preferred_Name | Nastorazepide Calcium
|
| FDA_UNII_Code | GZ3I1DMI8Q
|
| Contributing_Source | FDA
|
| Maps_To | Gastrin/cholecystokinin Type B Receptor Inhibitor Z-360
|
| CAS_Registry | 343326-69-2
|
| NCI_Drug_Dictionary_ID | 485295
|
| Legacy Concept Name | Z-360
|
| PubMedID_Primary_Reference | 17961733
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 485295
|
| Semantic_Type | Pharmacologic Substance
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |